BioNeutra International, Ltd.
BIMO · OTC
10/31/2022 | 10/31/2021 | 10/31/2020 | 10/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.37 | 0.19 | -0.56 | 0.00 |
| FCF Yield | -0.02% | 0.00% | 0.11% | -0.00% |
| EV / EBITDA | -15.32 | -4.73 | -188.50 | -4,292.27 |
| Quality | ||||
| ROIC | 18.35% | 24.16% | 33.94% | 7.31% |
| Gross Margin | 0.00% | 0.00% | 79.34% | 0.00% |
| Cash Conversion Ratio | 0.00 | -0.19 | 0.02 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | 321,132.23% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 6,582.08% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.22 | 0.04 |
| Interest Coverage | -4.02 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -7,164.34 | 0.00 |